Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0015695 (
fatty liver
)
13,941
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Hepatocellular lipid accumulation is a hallmark of non-alcoholicfatty liver disease (NAFLD), which encompasses a spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) and ultimately cirrhosis.
Zinc finger protein 267
(
ZNF267
) belongs to the family of Kruppel-like transcription factors, which regulate diverse biological processes that include development, proliferation, and differentiation. We have previously demonstrated that
ZNF267
expression is up-regulated in liver cirrhosis and is further increased in hepatocellular carcinoma (HCC). Here, we analyzed the expression of
ZNF267
in tissue specimens of NAFLD patients and found a significant up-regulation compared to normal liver tissue. Noteworthy,
ZNF267
mRNA was already significantly increased in steatotic liver tissue without inflammation. In line with this, incubation of primary human hepatocytes with palmitic acid induced a dose-dependent lipid accumulation and corresponding dose-dependent
ZNF267
induction in vitro. Furthermore, hepatocellular lipid accumulation induced formation of reactive oxygen species (ROS), and also chemically induced ROS formation increased
ZNF267
mRNA expression. In summary with previous findings, which revealed
ZNF267
as pro-fibrogenic and pro-cancerogenic factor in chronic liver disease, the present study further suggests
ZNF267
as promising therapeutic target particularly for NAFLD patients. In addition, it further indicates that
hepatic steatosis
per se has pathophysiological relevance and should not be considered as benign.
...
PMID:Increased expression of zinc finger protein 267 in non-alcoholic fatty liver disease. 2207 66